Treatment Details – 12.7 months
|Patients: This Phase II study involved 28 patients with mesothelioma, of whom 26 were evaluated. Twenty-two patients were men, and six were women. The median age was 63 years. Twenty-two patients had stage 3 or 4 disease. None of the patients had received prior treatment.|
Treatment: The treatment consisted of two chemotherapeutic agents: epirubicin and gemcitabine. In addition, the six patients who responded to chemotherapy were also administered interleukin.
Toxicities: Grade 3-4 toxicities included: leukocytopenia, nausea, and vomiting.
Results: In 26 evaluable patients, the median survival was 12.7 months.
Correspondence: Dr Luigi Portalone, MD